Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VNDA vs SUPN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SUPN Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

SUPN Overall Winner 6-Pillar Tally: VNDA 0 – 6 SUPN Matrix Metrics: VNDA 2 – 8 SUPN

As of Nov 16, 2026, Supernus Pharmaceuticals, Inc. (SUPN) is the stronger overall head-to-head candidate over Vanda Pharmaceuticals Inc. (VNDA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VNDA carries a Unified Composite Score of 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin), whereas SUPN carries 51.3/100 (HOLD) at $28.90 (7.4x Forward P/E, 46.9% operating margin).

  • Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile SUPN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VNDA vs SUPN
VNDA NASDAQ
Vanda Pharmaceuticals Inc.
Pharmaceutical Preparations
$3.79
-4.89% 1D
Market Cap $238.9M
TTM Revenue $229M
Forward P/E 103.1x
Beta / 30D Vol 1.25β · 61% Vol
Unified Composite Score
49.0 / 100 HOLD
Tech 56.0 Fund 58.0 Flow 65.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.9%), weak momentum, RSI 40
RSI-14: 40.0 · SMA20: $3.95 · SMA50: $4.46
SUPN NASDAQ Head-to-Head Winner
Supernus Pharmaceuticals, Inc.
Pharmaceutical Preparations
$28.90
-2.76% 1D
Market Cap $6.1B
TTM Revenue $1.37B
Forward P/E 7.4x
Beta / 30D Vol 0.76β · 125% Vol
Unified Composite Score
51.3 / 100 HOLD
Tech 58.0 Fund 63.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.4%), weak momentum, RSI 31
RSI-14: 30.9 · SMA20: $34.72 · SMA50: $39.26

6-Pillar Scorecard Institutional Category Breakdown (VNDA 0 – 6 SUPN)

Columns: Metric · VNDA · SUPN
1. Valuation Multiples SUPN
Forward P/E 103.1x 7.4x
Trailing P/E 103.1x 20.2x
PEG Ratio 2.23x 1.47x
EV / Revenue 0.9x 4.3x
2. Growth & Scale SUPN
Revenue Growth (YoY) +24.1% +13.4%
Earnings Growth (YoY) -95.9% +239.4%
TTM Revenue (USD) $229M $1.37B
Market Cap $238.9M $6.1B
3. Profitability & Quality SUPN
Gross Margin 93.6% 85.7%
Operating Margin -77.6% 46.9%
Net Profit Margin -119.9% 32.8%
Return on Equity (ROE) -82.5% -4.2%
4. Balance Sheet & Cash Flow SUPN
Cash Generation (TTM) -$150M $87M
Cash Flow Margin -65.4% 6.3%
Net Cash / Leverage $40M Net Cash $140M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SUPN
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 163.3% (75th %ile) 81.3% (20th %ile)
Put/Call OI Skew N/A 0.59x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat SUPN
OpEx & R&D Intensity N/A 38.8% of Rev ($533M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VNDA (2) vs SUPN (8)
Institutional Metric VNDA SUPN Criterion Row Edge
Market Capitalization
Scale
$238.9M $6.1B Larger Scale SUPN
Trailing P/E Ratio
Valuation
103.1x 20.2x Lower Multiple SUPN
Forward P/E Ratio
Valuation
103.1x 7.4x Lower Multiple SUPN
Revenue Growth (YoY)
Growth
+24.1% +13.4% Higher Growth VNDA
Operating Margin (TTM)
Profitability
-77.6% 46.9% Higher Margin SUPN
Net Profit Margin
Profitability
-119.9% 32.8% Higher Margin SUPN
Return on Equity (ROE)
Capital Efficiency
-82.5% -4.2% Higher ROE SUPN
52-Week Range Position
Momentum
4% ($4–$10) 9% ($26–$60) Stronger Trend SUPN
Beta / 30D Volatility
Risk Regime
1.25β · 61% Vol 0.76β · 125% Vol Lower Realized Risk VNDA
Unified Institutional Score
Composite Signal
49.0 / 100 (HOLD) 51.3 / 100 (HOLD) Higher Composite SUPN
Trailing 12M Revenue (USD)
Operating Scale
$229M $1.37B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
93.6% 85.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.23x PEG · 0.9x EV/Rev 1.47x PEG · 4.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$150M ($40M Net Cash) $87M ($140M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VNDA +16.46 pp
VNDA: -10.5% · SUPN: -26.96%
3M Horizon VNDA +12.28 pp
VNDA: -27.85% · SUPN: -40.13%
6M Horizon VNDA +1.96 pp
VNDA: -39.57% · SUPN: -41.53%
1Y Horizon VNDA +22.41 pp
VNDA: -12.56% · SUPN: -34.97%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VNDA Revenue SUPN Revenue VNDA Op. Margin SUPN Op. Margin Margin Leader
FY2018 $190M $410M 11.3% 35.3% SUPN
FY2019 $230M $390M 10.0% 37.8% SUPN
FY2020 $250M $520M 11.0% 33.4% SUPN
FY2021 $270M $580M 15.7% 14.8% VNDA
FY2022 $250M $670M 2.5% 6.9% SUPN
FY2023 $190M $610M -7.2% -0.9% SUPN
FY2024 $200M $660M -20.5% 12.3% SUPN
FY2025 $220M $720M -70.0% -8.7% SUPN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VNDA BREAKDOWN
174d in phase · OBV NEUTRAL
Current IV 163.3%
IV Percentile 75th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VNDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SUPN BREAKDOWN
91d in phase · OBV ACCUMULATION
Current IV 81.3%
IV Percentile 20th %ile
Put/Call OI Skew 0.59x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact SUPN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VNDA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.9M market capitalization and -77.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SUPN Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $6.1B market capitalization and 46.9% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($533M)
90D Engineering Disclosures 0 Published

Investor FAQ VNDA vs SUPN Key Questions & Quantitative Answers

As of Nov 16, 2026, Supernus Pharmaceuticals, Inc. (SUPN) is the stronger overall head-to-head candidate over Vanda Pharmaceuticals Inc. (VNDA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VNDA carries a Unified Composite Score of 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin), whereas SUPN carries 51.3/100 (HOLD) at $28.90 (7.4x Forward P/E, 46.9% operating margin). Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile SUPN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SUPN leads the Growth & Scale pillar: VNDA posts +24.1% YoY revenue growth and -95.9% YoY earnings growth on $229M TTM revenue (93.6% gross margin, -77.6% operating margin), compared with SUPN at +13.4% YoY revenue growth and +239.4% YoY earnings growth on $1.37B TTM revenue (85.7% gross margin, 46.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VNDA cumulative revenue shifted +15.8% while SUPN shifted +75.6%. In operating R&D and SG&A reinvestment, VNDA deploys N/A (0 90-day corporate R&D disclosures) versus 38.8% of Rev ($533M) (0 disclosures) for SUPN.

SUPN screens cheaper on headline valuation multiples. VNDA trades at 103.1x Forward P/E, 103.1x Trailing P/E, 2.23x PEG, and 0.9x EV/Revenue (-65.4% FCF margin), whereas SUPN trades at 7.4x Forward P/E, 20.2x Trailing P/E, 1.47x PEG, and 4.3x EV/Revenue (6.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VNDA (-82.5% ROE) versus SUPN (-4.2% ROE) capital efficiency.

In options market volatility and institutional positioning, VNDA carries 163.3% implied volatility (75th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.25β · 61% Vol realized risk). By comparison, SUPN carries 81.3% implied volatility (20th %ile, Compressed (<25th %ile)), a 0.59x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.76β · 125% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.